Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

BRIEF-Sierra Oncology Significantly Expands Clinical Development Program

Published 2018-02-27, 07:26 a/m
© Reuters.  BRIEF-Sierra Oncology Significantly Expands Clinical Development Program
SRRA
-

Sierra Oncology Inc SRRA.O :

* SIERRA ONCOLOGY SIGNIFICANTLY EXPANDS CLINICAL DEVELOPMENT PROGRAM

* SIERRA ONCOLOGY INC - ADDING NEW SRA737 MONOTHERAPY COHORT FOR CCNE1-DRIVEN OVARIAN CANCER

* SIERRA ONCOLOGY INC - SRA141 IND SUBMISSION PLANNED IN H2 2018

* SIERRA ONCOLOGY - ONGOING SRA737 CLINICAL STUDIES EXPANDED TO TARGET AGGREGATE ENROLLMENT OF 200 PATIENTS ACROSS TEN CANCER INDICATIONS

* SIERRA ONCOLOGY - TO INITIATE PHASE 1B/2 TRIAL IN Q4 TO EVALUATE SRA737 WITH ZEJULA TO TREAT METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

* SIERRA ONCOLOGY - EXPANDING NUMBER OF ACTIVE SITES RECRUITING PATIENTS INTO SRA737-01 PHASE 1/2 MONOTHERAPY TRIAL FROM 3 TO 15

* SIERRA ONCOLOGY - MAJORITY OF REPORTED ADVERSE EVENTS IN SRA737-02 PHASE 1/2 LDG COMBINATION TRIAL HAVE BEEN GRADE 1 OR GRADE 2 IN SEVERITY

* SIERRA ONCOLOGY - ONLY ONE GRADE 3 TREATMENT RELATED AE (NEUTROPENIA) WAS OBSERVED, AT 40 MG SRA737/300 MG/M(2) GEMCITABINE

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.